Monocyte chemoattractant protein-1 in patients with peripheral arterial disease
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
15203564
PubMed Central
PMC1781535
DOI
10.1080/09629350410001664752
PII: 9R1FUG1P3ATM7EKH
Knihovny.cz E-zdroje
- MeSH
- arterie * MeSH
- arterioskleróza etiologie MeSH
- biologické markery krev MeSH
- chemokin CCL2 krev MeSH
- ELISA MeSH
- hypertenze komplikace MeSH
- imunoanalýza MeSH
- komplikace diabetu MeSH
- kouření škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipidy krev MeSH
- onemocnění periferních cév krev komplikace MeSH
- pilotní projekty MeSH
- rizikové faktory MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- biologické markery MeSH
- chemokin CCL2 MeSH
- lipidy MeSH
BACKGROUND: Chemokine-driven migration of inflammatory cells has been implicated in the pathogenesis of atherosclerotic conditions including peripheral arterial disease (PAD). Monocyte chemoattractant protein-1 (MCP-1) is elevated in patients with coronary artery disease and in hypertensive patients. This study therefore investigated MCP-1 in patients with PAD. METHODS: Serum MCP-1 was determined by enzyme-linked immunosorbent assay in 36 healthy, control subjects and in 19 patients with PAD. Statistical analysis utilised the Mann-Whitney test and Spearman correlation (p < 0.05). RESULTS: MCP-1 (pg/ml) was increased in patients compared with in controls (mean+/-standard error of the mean: PAD group, 748+/-60; control group, 459+/-27; p=0.0001). MCP-1 levels tended to decrease with progressing disease. From atherosclerosis risk factors, diabetes inclined to increase MCP-1 levels; hypertension had no effect. Serum MCP-1 correlated with cholesterol, triglycerides, low-density lipoprotein but not high-density lipoprotein. CONCLUSION: Elevation of MCP-1 in the circulation of PAD patients shown in the present pilot study implicates this CC chemokine ligand 2 in inflammatory processes contributing to PAD clinical symptomatology. Further investigations are necessary to evaluate whether MCP-1 can be used as a potential marker of peripheral arterial disease follow-up and/or prognosis.
Zobrazit více v PubMed
Nat Immunol. 2001 Feb;2(2):108-15 PubMed
Nat Immunol. 2001 Feb;2(2):95-101 PubMed
Biochem Biophys Res Commun. 2001 Jun 1;284(1):239-44 PubMed
Clin Exp Immunol. 2001 Jun;124(3):343-5 PubMed
Clin Exp Immunol. 2001 Jun;124(3):346-52 PubMed
Lancet. 2001 Oct 13;358(9289):1257-64 PubMed
Am Heart J. 2003 Feb;145(2):330-3 PubMed
Thromb Haemost. 2003 Jun;89(6):1058-63 PubMed
Am J Cardiol. 2003 Jul 15;92(2):194-9 PubMed
Vasc Med. 2003 May;8(2):95-100 PubMed
Circulation. 1992 Dec;86(6 Suppl):III20-5 PubMed
J Mol Cell Cardiol. 1997 Jan;29(1):419-23 PubMed
Arterioscler Thromb Vasc Biol. 1998 Feb;18(2):185-92 PubMed
Circulation. 1998 Mar 31;97(12):1136-43 PubMed
Am J Cardiol. 1999 Nov 1;84(9):999-1003 PubMed
Clin Nutr. 1999 Oct;18(5):281-9 PubMed
Diabetes Res Clin Pract. 2000 May;48(2):127-38 PubMed
Cardiovasc Res. 2000 Sep;47(4):778-87 PubMed
Am J Pathol. 2001 Feb;158(2):715-21 PubMed
Transfusion. 2001 Mar;41(3):378-81 PubMed
Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction
